Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Breast Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
HER2 Negative Breast Cancer (431
)
HER2 Positive Breast Cancer (429
)
Triple Negative Breast Cancer (319
)
Hormone Receptor Positive Breast Cancer (304
)
Estrogen Receptor Positive Breast Cancer (202
)
Male Breast Cancer (10
)
Hormone Receptor Negative Breast Cancer (3
)
HER2 Negative Breast Cancer (431
)
HER2 Positive Breast Cancer (429
)
Triple Negative Breast Cancer (319
)
Hormone Receptor Positive Breast Cancer (304
)
Estrogen Receptor Positive Breast Cancer (202
)
Male Breast Cancer (10
)
Hormone Receptor Negative Breast Cancer (3
)
›
Associations
(2094)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
ASCO 2023 - 3 days (New C3)
trastuzumab + pertuzumab
Sensitive
:
A1
ASCO 2023 - 3d
trastuzumab + pertuzumab
Sensitive: A1 - Approval
ASCO 2023 - 3 days
trastuzumab + pertuzumab
Sensitive
:
A1
ASCO 2023 - 3 days - (New C3)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
ASCO 2023 - 3 days (New B)
sacituzumab govitecan-hziy
Sensitive
:
A1
ASCO 2023 - 3d
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
ASCO 2023 - 3 days
sacituzumab govitecan-hziy
Sensitive
:
A1
ASCO 2023 - 3 days - (New B)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A1 - Approval
ASCO 2023 - 3 days (New B)
abemaciclib
Sensitive
:
A1
ASCO 2023 - 3d
abemaciclib
Sensitive: A1 - Approval
ASCO 2023 - 3 days
abemaciclib
Sensitive
:
A1
ASCO 2023 - 3 days - (New B)
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: B - Late Trials
ASCO 2023 - 3 days (New B)
palbociclib
Sensitive
:
B
ASCO 2023 - 3d
palbociclib
Sensitive: B - Late Trials
ASCO 2023 - 3 days
palbociclib
Sensitive
:
B
ASCO 2023 - 3 days - (New B)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
G1T38
Sensitive: B - Late Trials
ASCO 2023 - 3 days (New B)
G1T38
Sensitive
:
B
ASCO 2023 - 3d
G1T38
Sensitive: B - Late Trials
ASCO 2023 - 3 days
G1T38
Sensitive
:
B
ASCO 2023 - 3 days - (New B)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
dalpiciclib
Sensitive: B - Late Trials
ASCO 2023 - 3 days (New C3)
dalpiciclib
Sensitive
:
B
ASCO 2023 - 3d
dalpiciclib
Sensitive: B - Late Trials
ASCO 2023 - 3 days
dalpiciclib
Sensitive
:
B
ASCO 2023 - 3 days - (New C3)
ERBB3 expression
Breast Cancer
ERBB3 expression
Breast Cancer
U3-1402
Sensitive: C2 – Inclusion Criteria
ASCO 2023 - 3 days (New C3)
U3-1402
Sensitive
:
C2
ASCO 2023 - 3d
U3-1402
Sensitive: C2 – Inclusion Criteria
ASCO 2023 - 3 days
U3-1402
Sensitive
:
C2
ASCO 2023 - 3 days - (New C3)
HER-2 expression
Breast Cancer
HER-2 expression
Breast Cancer
DF1001
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days (New C3)
DF1001
Sensitive
:
C3
ASCO 2023 - 3d
DF1001
Sensitive: C3 – Early Trials
ASCO 2023 - 3 days
DF1001
Sensitive
:
C3
ASCO 2023 - 3 days - (New C3)
ESR1 mutation + PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
ESR1 mutation + PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Resistant: A2 - Guideline
ASCO.org - 1 week (New A2)
alpelisib
Resistant
:
A2
ASCO.org - 1wk
alpelisib
Resistant: A2 - Guideline
ASCO.org - 1 week
alpelisib
Resistant
:
A2
ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
elacestrant
Sensitive: A2 - Guideline
ASCO.org - 1 week (New A2)
elacestrant
Sensitive
:
A2
ASCO.org - 1wk
elacestrant
Sensitive: A2 - Guideline
ASCO.org - 1 week
elacestrant
Sensitive
:
A2
ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
everolimus
Sensitive: A2 - Guideline
ASCO.org - 1 week (New A2)
everolimus
Sensitive
:
A2
ASCO.org - 1wk
everolimus
Sensitive: A2 - Guideline
ASCO.org - 1 week
everolimus
Sensitive
:
A2
ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
ASCO.org - 1 week (New A2)
tamoxifen
Sensitive
:
A2
ASCO.org - 1wk
tamoxifen
Sensitive: A2 - Guideline
ASCO.org - 1 week
tamoxifen
Sensitive
:
A2
ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
Aromatase inhibitor
Sensitive: A2 - Guideline
ASCO.org - 1 week (New A2)
Aromatase inhibitor
Sensitive
:
A2
ASCO.org - 1wk
Aromatase inhibitor
Sensitive: A2 - Guideline
ASCO.org - 1 week
Aromatase inhibitor
Sensitive
:
A2
ASCO.org - 1 week - (New A2)
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
ESR1 mutation + HR positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A2 - Guideline
ASCO.org - 1 week (New A2)
fulvestrant
Sensitive
:
A2
ASCO.org - 1wk
fulvestrant
Sensitive: A2 - Guideline
ASCO.org - 1 week
fulvestrant
Sensitive
:
A2
ASCO.org - 1 week - (New A2)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: A1 - Approval
J Clin Oncol - 1 week (New C3)
ribociclib
Sensitive
:
A1
J Clin Oncol - 1wk
ribociclib
Sensitive: A1 - Approval
J Clin Oncol - 1 week
ribociclib
Sensitive
:
A1
J Clin Oncol - 1 week - (New C3)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
U3-1402
Sensitive: C2 – Inclusion Criteria
Ann Oncol - 1 week (New C3)
U3-1402
Sensitive
:
C2
Ann Oncol - 1wk
U3-1402
Sensitive: C2 – Inclusion Criteria
Ann Oncol - 1 week
U3-1402
Sensitive
:
C2
Ann Oncol - 1 week - (New C3)
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
enzalutamide capsule + fulvestrant
Sensitive: C3 – Early Trials
NPJ Breast Cancer - 1 week (New C3)
enzalutamide capsule + fulvestrant
Sensitive
:
C3
NPJ Breast Cancer - 1wk
enzalutamide capsule + fulvestrant
Sensitive: C3 – Early Trials
NPJ Breast Cancer - 1 week
enzalutamide capsule + fulvestrant
Sensitive
:
C3
NPJ Breast Cancer - 1 week - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
tucatinib
Sensitive: B - Late Trials
J Natl Cancer Inst - 2 weeks (New D)
tucatinib
Sensitive
:
B
J Natl Cancer Inst - 2wk
tucatinib
Sensitive: B - Late Trials
J Natl Cancer Inst - 2 weeks
tucatinib
Sensitive
:
B
J Natl Cancer Inst - 2 weeks - (New D)
BRCA1 mutation
HER2 Negative Breast Cancer
BRCA1 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
NICE - 2 weeks (New A2)
olaparib
Sensitive
:
A1
NICE - 2wk
olaparib
Sensitive: A1 - Approval
NICE - 2 weeks
olaparib
Sensitive
:
A1
NICE - 2 weeks - (New A2)
BRCA2 mutation
HER2 Negative Breast Cancer
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
NICE - 2 weeks (New A2)
olaparib
Sensitive
:
A1
NICE - 2wk
olaparib
Sensitive: A1 - Approval
NICE - 2 weeks
olaparib
Sensitive
:
A1
NICE - 2 weeks - (New A2)
HR positive
HER2 Positive Breast Cancer
HR positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
JAMA Oncol - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
A2
JAMA Oncol - 2wk
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
JAMA Oncol - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
A2
JAMA Oncol - 2 weeks - (New C3)
TSC2 C1450G
HER2 Positive Breast Cancer
TSC2 C1450G
HER2 Positive Breast Cancer
palbociclib + lapatinib
Sensitive: D – Preclinical
NPJ Breast Cancer - 2 weeks (New D)
palbociclib + lapatinib
Sensitive
:
D
NPJ Breast Cancer - 2wk
palbociclib + lapatinib
Sensitive: D – Preclinical
NPJ Breast Cancer - 2 weeks
palbociclib + lapatinib
Sensitive
:
D
NPJ Breast Cancer - 2 weeks - (New D)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
TCHP
Sensitive: A2 - Guideline
ESMO-BC 2023 - 3 weeks (New C3)
TCHP
Sensitive
:
A2
ESMO-BC 2023 - 3wk
TCHP
Sensitive: A2 - Guideline
ESMO-BC 2023 - 3 weeks
TCHP
Sensitive
:
A2
ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
ESMO-BC 2023 - 3 weeks (New C3)
trastuzumab + lapatinib
Sensitive
:
A2
ESMO-BC 2023 - 3wk
trastuzumab + lapatinib
Sensitive: A2 - Guideline
ESMO-BC 2023 - 3 weeks
trastuzumab + lapatinib
Sensitive
:
A2
ESMO-BC 2023 - 3 weeks - (New C3)
HR positive
HER2 Positive Breast Cancer
HR positive
HER2 Positive Breast Cancer
Aromatase inhibitor
Sensitive: A2 - Guideline
ESMO-BC 2023 - 3 weeks (New C3)
Aromatase inhibitor
Sensitive
:
A2
ESMO-BC 2023 - 3wk
Aromatase inhibitor
Sensitive: A2 - Guideline
ESMO-BC 2023 - 3 weeks
Aromatase inhibitor
Sensitive
:
A2
ESMO-BC 2023 - 3 weeks - (New C3)
PD-L1 overexpression
Triple Negative Breast Cancer
PD-L1 overexpression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: B - Late Trials
ESMO-BC 2023 - 3 weeks (New B)
pembrolizumab
Sensitive
:
B
ESMO-BC 2023 - 3wk
pembrolizumab
Sensitive: B - Late Trials
ESMO-BC 2023 - 3 weeks
pembrolizumab
Sensitive
:
B
ESMO-BC 2023 - 3 weeks - (New B)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
AZD5363
Sensitive: B - Late Trials
ESMO-BC 2023 - 3 weeks (New B)
AZD5363
Sensitive
:
B
ESMO-BC 2023 - 3wk
AZD5363
Sensitive: B - Late Trials
ESMO-BC 2023 - 3 weeks
AZD5363
Sensitive
:
B
ESMO-BC 2023 - 3 weeks - (New B)
HER-2 underexpression + ER underexpression
Breast Cancer
HER-2 underexpression + ER underexpression
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
ESMO-BC 2023 - 3 weeks (New B)
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
ESMO-BC 2023 - 3wk
fam-trastuzumab deruxtecan-nxki
Sensitive: B - Late Trials
ESMO-BC 2023 - 3 weeks
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
ESMO-BC 2023 - 3 weeks - (New B)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
ESMO-BC 2023 - 3 weeks (New C3)
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
ESMO-BC 2023 - 3wk
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
ESMO-BC 2023 - 3 weeks
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
ESMO-BC 2023 - 3 weeks (New C3)
trastuzumab
Sensitive
:
A1
ESMO-BC 2023 - 3wk
trastuzumab
Sensitive: A1 - Approval
ESMO-BC 2023 - 3 weeks
trastuzumab
Sensitive
:
A1
ESMO-BC 2023 - 3 weeks - (New C3)
HR positive
HER2 Positive Breast Cancer
HR positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
ESMO-BC 2023 - 3 weeks (New C3)
neratinib
Sensitive
:
A1
ESMO-BC 2023 - 3wk
neratinib
Sensitive: A1 - Approval
ESMO-BC 2023 - 3 weeks
neratinib
Sensitive
:
A1
ESMO-BC 2023 - 3 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
ESMO-BC 2023 - 3 weeks (New C3)
palbociclib
Sensitive
:
A1
ESMO-BC 2023 - 3wk
palbociclib
Sensitive: A1 - Approval
ESMO-BC 2023 - 3 weeks
palbociclib
Sensitive
:
A1
ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
ESMO-BC 2023 - 3 weeks (New C3)
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
ESMO-BC 2023 - 3wk
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
ESMO-BC 2023 - 3 weeks
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
ESMO-BC 2023 - 3 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
ESMO-BC 2023 - 3 weeks (New C3)
capecitabine
Sensitive
:
A2
ESMO-BC 2023 - 3wk
capecitabine
Sensitive: A2 - Guideline
ESMO-BC 2023 - 3 weeks
capecitabine
Sensitive
:
A2
ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab + ado-trastuzumab emtansine
Sensitive: B - Late Trials
ESMO-BC 2023 - 3 weeks (New C3)
pertuzumab + ado-trastuzumab emtansine
Sensitive
:
B
ESMO-BC 2023 - 3wk
pertuzumab + ado-trastuzumab emtansine
Sensitive: B - Late Trials
ESMO-BC 2023 - 3 weeks
pertuzumab + ado-trastuzumab emtansine
Sensitive
:
B
ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive: B - Late Trials
ESMO-BC 2023 - 3 weeks (New C3)
trastuzumab-dkst
Sensitive
:
B
ESMO-BC 2023 - 3wk
trastuzumab-dkst
Sensitive: B - Late Trials
ESMO-BC 2023 - 3 weeks
trastuzumab-dkst
Sensitive
:
B
ESMO-BC 2023 - 3 weeks - (New C3)
HRD
Triple Negative Breast Cancer
HRD
Triple Negative Breast Cancer
olaparib
Sensitive: C1 - Off-label
ESMO-BC 2023 - 3 weeks (New C3)
olaparib
Sensitive
:
C1
ESMO-BC 2023 - 3wk
olaparib
Sensitive: C1 - Off-label
ESMO-BC 2023 - 3 weeks
olaparib
Sensitive
:
C1
ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
capecitabine + vinorelbine tartrate
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2023 - 3 weeks (New C3)
capecitabine + vinorelbine tartrate
Sensitive
:
C2
ESMO-BC 2023 - 3wk
capecitabine + vinorelbine tartrate
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2023 - 3 weeks
capecitabine + vinorelbine tartrate
Sensitive
:
C2
ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
ZW25
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2023 - 3 weeks (New C3)
ZW25
Sensitive
:
C2
ESMO-BC 2023 - 3wk
ZW25
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2023 - 3 weeks
ZW25
Sensitive
:
C2
ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + atezolizumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2023 - 3 weeks (New C3)
trastuzumab + atezolizumab + pertuzumab
Sensitive
:
C2
ESMO-BC 2023 - 3wk
trastuzumab + atezolizumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2023 - 3 weeks
trastuzumab + atezolizumab + pertuzumab
Sensitive
:
C2
ESMO-BC 2023 - 3 weeks - (New C3)
HER-2 negative
Triple Negative Breast Cancer
HER-2 negative
Triple Negative Breast Cancer
U3-1402
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2023 - 3 weeks (New C3)
U3-1402
Sensitive
:
C2
ESMO-BC 2023 - 3wk
U3-1402
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2023 - 3 weeks
U3-1402
Sensitive
:
C2
ESMO-BC 2023 - 3 weeks - (New C3)
HRD
Triple Negative Breast Cancer
HRD
Triple Negative Breast Cancer
olaparib + durvalumab
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2023 - 3 weeks (New C3)
olaparib + durvalumab
Sensitive
:
C2
ESMO-BC 2023 - 3wk
olaparib + durvalumab
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2023 - 3 weeks
olaparib + durvalumab
Sensitive
:
C2
ESMO-BC 2023 - 3 weeks - (New C3)
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
ARV-471
Sensitive: C3 – Early Trials
ESMO-BC 2023 - 3 weeks (New C3)
ARV-471
Sensitive
:
C3
ESMO-BC 2023 - 3wk
ARV-471
Sensitive: C3 – Early Trials
ESMO-BC 2023 - 3 weeks
ARV-471
Sensitive
:
C3
ESMO-BC 2023 - 3 weeks - (New C3)
BRCA1 mutation
Triple Negative Breast Cancer
BRCA1 mutation
Triple Negative Breast Cancer
Immunotherapy
Resistant: C3 – Early Trials
ESMO-BC 2023 - 3 weeks (New C3)
Immunotherapy
Resistant
:
C3
ESMO-BC 2023 - 3wk
Immunotherapy
Resistant: C3 – Early Trials
ESMO-BC 2023 - 3 weeks
Immunotherapy
Resistant
:
C3
ESMO-BC 2023 - 3 weeks - (New C3)
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
Immunotherapy
Resistant: C3 – Early Trials
ESMO-BC 2023 - 3 weeks (New C3)
Immunotherapy
Resistant
:
C3
ESMO-BC 2023 - 3wk
Immunotherapy
Resistant: C3 – Early Trials
ESMO-BC 2023 - 3 weeks
Immunotherapy
Resistant
:
C3
ESMO-BC 2023 - 3 weeks - (New C3)
HR positive + HER-2 negative
Male Breast Cancer
HR positive + HER-2 negative
Male Breast Cancer
CDK4 inhibitor + CDK6 inhibitor
Sensitive: C3 – Early Trials
ESMO-BC 2023 - 3 weeks (New C3)
CDK4 inhibitor + CDK6 inhibitor
Sensitive
:
C3
ESMO-BC 2023 - 3wk
CDK4 inhibitor + CDK6 inhibitor
Sensitive: C3 – Early Trials
ESMO-BC 2023 - 3 weeks
CDK4 inhibitor + CDK6 inhibitor
Sensitive
:
C3
ESMO-BC 2023 - 3 weeks - (New C3)
HR positive + HER-2 underexpression
Breast Cancer
HR positive + HER-2 underexpression
Breast Cancer
U3-1402
Sensitive: C3 – Early Trials
ESMO-BC 2023 - 3 weeks (New C3)
U3-1402
Sensitive
:
C3
ESMO-BC 2023 - 3wk
U3-1402
Sensitive: C3 – Early Trials
ESMO-BC 2023 - 3 weeks
U3-1402
Sensitive
:
C3
ESMO-BC 2023 - 3 weeks - (New C3)
ESR1 mutation
Breast Cancer
ESR1 mutation
Breast Cancer
abemaciclib
Sensitive: C3 – Early Trials
JCO Precis Oncol - 3 weeks (New C3)
abemaciclib
Sensitive
:
C3
JCO Precis Oncol - 3wk
abemaciclib
Sensitive: C3 – Early Trials
JCO Precis Oncol - 3 weeks
abemaciclib
Sensitive
:
C3
JCO Precis Oncol - 3 weeks - (New C3)
HR positive + ER overexpression
HER2 Negative Breast Cancer
HR positive + ER overexpression
HER2 Negative Breast Cancer
palbociclib
Sensitive: C3 – Early Trials
ESMO-BC 2023 - 3 weeks (New C3)
palbociclib
Sensitive
:
C3
ESMO-BC 2023 - 3wk
palbociclib
Sensitive: C3 – Early Trials
ESMO-BC 2023 - 3 weeks
palbociclib
Sensitive
:
C3
ESMO-BC 2023 - 3 weeks - (New C3)
HR positive + ER overexpression
HER2 Negative Breast Cancer
HR positive + ER overexpression
HER2 Negative Breast Cancer
ribociclib
Sensitive: C3 – Early Trials
ESMO-BC 2023 - 3 weeks (New C3)
ribociclib
Sensitive
:
C3
ESMO-BC 2023 - 3wk
ribociclib
Sensitive: C3 – Early Trials
ESMO-BC 2023 - 3 weeks
ribociclib
Sensitive
:
C3
ESMO-BC 2023 - 3 weeks - (New C3)
CCDC6-RET fusion
Triple Negative Breast Cancer
CCDC6-RET fusion
Triple Negative Breast Cancer
pralsetinib
Sensitive: C4 – Case Studies
Oncologist - 3 weeks (New C4)
pralsetinib
Sensitive
:
C4
Oncologist - 3wk
pralsetinib
Sensitive: C4 – Case Studies
Oncologist - 3 weeks
pralsetinib
Sensitive
:
C4
Oncologist - 3 weeks - (New C4)
TROP2 overexpression
Breast Cancer
TROP2 overexpression
Breast Cancer
DS-1062a
Sensitive: D – Preclinical
ESMO-BC 2023 - 3 weeks (New D)
DS-1062a
Sensitive
:
D
ESMO-BC 2023 - 3wk
DS-1062a
Sensitive: D – Preclinical
ESMO-BC 2023 - 3 weeks
DS-1062a
Sensitive
:
D
ESMO-BC 2023 - 3 weeks - (New D)
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
ado-trastuzumab emtansine
Sensitive
:
A1
ado-trastuzumab emtansine
Sensitive: A1 - Approval
ado-trastuzumab emtansine
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
TAC
Sensitive: A1 - Approval
TAC
Sensitive
:
A1
TAC
Sensitive: A1 - Approval
TAC
Sensitive
:
A1
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: A1 - Approval
alpelisib
Sensitive
:
A1
alpelisib
Sensitive: A1 - Approval
alpelisib
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
pegylated liposomal doxorubicin
Sensitive
:
A1
pegylated liposomal doxorubicin
Sensitive: A1 - Approval
pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Breast Cancer
No biomarker
Breast Cancer
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
bevacizumab-bvzr
Sensitive: A1 - Approval
bevacizumab-bvzr
Sensitive
:
A1
HR positive
Hormone Receptor Positive Breast Cancer
HR positive
Hormone Receptor Positive Breast Cancer
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login